Advertisement

Digestive Diseases and Sciences

, Volume 59, Issue 10, pp 2462–2469 | Cite as

Vitamin D and S-Farnesylthiosalicylic Acid Have a Synergistic Effect on Hepatic Stellate Cells Proliferation

  • Rina Neeman
  • Shirley AbramovitchEmail author
  • Efrat Sharvit
  • Galit Elad-Sfadia
  • Roni Haklai
  • Yoel Kloog
  • Shimon Reif
Original Article

Abstract

Background

Hepatic stellate cells (HSCs) have a key role in the formation of hepatic fibrosis. The active form of vitamin D, 1,25(OH)2D3, has been found to have antiproliferative and antifibrotic effects in various tissues including liver. Farnesylthiosalicylic acid (FTS), a novel Ras antagonist, was also found to inhibit hepatic fibrosis.

Aims

The purpose of this study was to examine the antiproliferative and antifibrotic effects of the combined treatment of 1,25(OH)2D3 and FTS on primary cultured HSCs.

Methods

Primary HSCs, isolated from rat’s livers, were treated with 1,25(OH)2D3, FTS or a combination of both. Proliferation was assessed by bromodeoxyuridine. Expression of p-ERK, ERK, Ras-GTP, total-Ras, CyclinD1 and fibrotic markers was measured by western blotting analysis and real-time PCR. Cytotoxicity was assessed by lactate dehydrogenase method.

Results

The combined treatment inhibited HSCs proliferation by threefold. The effect was synergistic and non-cytotoxic. In concordance, the combined treatment suppressed CyclinD1 expression by ~2-fold, whereas 1,25(OH)2D3 or FTS alone showed a significantly lower inhibitory effect. The effect of the combined treatment on CyclinD1 expression was mediated via Ras-GTP and p-ERK signal transduction pathway. The effect on fibrotic markers showed that 1,25(OH)2D3 decreased collagen Iα1 expression by ~40 %, FTS by ~50 % and the combined treatment by ~60 %. 1,25(OH)2D3 inhibited tissue inhibitor of metalloproteinases-1 (TIMP-1) expression by 20 %. FTS alone or 1,25(OH)2D3 + FTS inhibited TIMP-1 expression by 60 %. FTS inhibited transforming growth factor-β (TGF-β) expression by 25 %, while 1,25(OH)2D3 had no effect.

Conclusion

Although the combination of 1,25(OH)2D3 and FTS did not demonstrate an additive antifibrotic effect, it showed a synergistic antiproliferative effect on primary HSCs. Therefore, the combined treatment may have a potential therapeutic value in the initiation of fibrotic process.

Keywords

Liver 1,25(OH)2D3 FTS Proliferation Fibrosis 

Notes

Acknowledgments

This work was performed in partial fulfillment of the M.D. thesis requirements of the Sackler Faculty of Medicine, Tel Aviv University.

Conflict of interest

None.

References

  1. 1.
    Friedman S. The cellular basis of hepatic fibrosis. N Engl J Med. 1993;328:1828–1835.PubMedCrossRefGoogle Scholar
  2. 2.
    Crawford JM. Cirrhosis. In: MacSween RNM, Anthony P, Scheuer PJ, Burt AD, Portmann BC, eds. Pathology of the Liver, 4th edn. Philadelphia, PA: WB Saunders; 2001:575–619.Google Scholar
  3. 3.
    Eng F, Friedman SL, Fibrogenesis I. New insight into hepatic stellate cell activation; the simple becomes complex. Am J Physiol. 2000;279:G7–G11.Google Scholar
  4. 4.
    Pinzani P, Marra F, Carloni V. Signal transduction in hepatic stellate cells. Liver. 1998;18:2–23.PubMedCrossRefGoogle Scholar
  5. 5.
    Arthur MJ. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2000;279:G245–G249.PubMedGoogle Scholar
  6. 6.
    Friedman S, Arthur MJ. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. J Clin Invest. 1989;84:1780–1785.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Starkel P, Lambotte L, Sempoux C, De Saeger C, et al. After portal branch ligation in the rat, cellular proliferation is associated with selective induction of Ha-Ras, P53, cycline E, and Cdk. Gut. 2000;49:119–130.Google Scholar
  8. 8.
    Lavoie JN, L’Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44 MAPK and negatively by the p38/HOG MAPK pathway. J Biol Chem. 1996;271:20608–20616.Google Scholar
  9. 9.
    Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA. 1992;89:6403–6407.Google Scholar
  10. 10.
    Marom M, Haklai R, Ben-Baruch G, Marciano D, Egozi Y, Kloog Y. Selective inhibition of ras-dependent cell growth by farnesyl thiosalicylic acid. J Biol Chem. 1995;270:22263–22270.PubMedCrossRefGoogle Scholar
  11. 11.
    Gana-Weisz M, Haklai R, Marciano D, Ben-Baruch G, Kloog Y. A Ras-dislodging antagonist interrupts MAPK activation. Biothem Bioph Res Comm. 1988;239:900–904.CrossRefGoogle Scholar
  12. 12.
    Reif S, Weisz B, Gana-Weisz M, Aeed H, et al. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats. J Hepatol. 1999;21:1053–1061.CrossRefGoogle Scholar
  13. 13.
    Zvibel I, Bar-Zohar D, Kloog Y, Oren R, Reif S. The effect of Ras inhibition on the proliferation, apoptosis and matrix metalloproteases activity in rat hepatic stellate cells. Dig Dis Sci. 2008;53:1048–1053.PubMedCrossRefGoogle Scholar
  14. 14.
    Reif S, Aeed H, Shilo Y, Reich R, et al. Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid. J Hepatol. 2004;41:235–241.PubMedCrossRefGoogle Scholar
  15. 15.
    Spina C, Ton L, Yao M, Maehr H, et al. Selective vitamin D receptor modulators and their effects on colorectal tumor growth. J Steroid Biochem Mol Biol. 2007;103:757–762.Google Scholar
  16. 16.
    Tan X. Therapeutic role and potential mechanisms of active Vitamin D in renal interstitial fibrosis. J Steroid Biochem Mol Biol. 2007;103:491–496.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Ramirez AM, Wongtrakool C, Welch T, et al. Vitamin D inhibition of pro-fibrotic effects of transformation growth factor b1 in lung fibroblasts and epithelial cells. J Steroid Biochem Mol Biol. 2010;118:142–150.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Abramovitch S, Dahan Bachar L, Sharvit E, Weisman Y, et al. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut. 2011;60:1728–1737.Google Scholar
  19. 19.
    Friedman SL, Roll FJ. Isolation and culture of hepatic lipocytes, Kupffer cells and sinusoidal endothelial cells by density gradient centrifugation with Stractan. Anal Biochem. 1987;161:207–218.PubMedCrossRefGoogle Scholar
  20. 20.
    Marciano D, Ben-Baruch G, Marom M, Ego Y, Haklai R, Kloog Y. Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras dependent cell growth. J Med Chem. 1995;38:1267–1272.Google Scholar
  21. 21.
    Ravid A, Koren R, Narinsky R, Rotem C, Novogrodsky A, Liberman A. 1,25-dihydroxyvitamin D3 and agents that increase intracellular adenosine 3’,5’-monophosphate synergistically inhibit the mitogenic stimulation of human lymphocytes. J Clin Endocrinol Metab. 1990;70:1687–1692.Google Scholar
  22. 22.
    Xu J, Kochanek KD, Murphy SL, Tejada-Vera B. Deaths: final data for 2007. Natl Vital Stat Rep. 2010;58:1–136.Google Scholar
  23. 23.
    Battaller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–218.CrossRefGoogle Scholar
  24. 24.
    Grant WB. Epidemiology of disease risks in relation to vitamin D insufficiency. Prog Biophys Mol Biol. 2006;92:65–79.PubMedCrossRefGoogle Scholar
  25. 25.
    Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, Leblanc M, Coulter S, He M, Scott C, Lau SL, Atkins AR, Barish GD, Gunton JE, Liddle C, Downes M, Evans RM. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell. 2013;153:601–613.Google Scholar
  26. 26.
    Bouillon R, Bischoff-Ferrari H, Willett W. Vitamin D and health: perspectives from mice and man. J Bone Miner Res. 2008;23: 974–979.Google Scholar
  27. 27.
    Samuel S, Sitrin MD. Vitamin D’s role in cell proliferation and differentiation. Nutr Rev. 2008;66:116–124.CrossRefGoogle Scholar
  28. 28.
    Hirose M, Nishino T, Obata Y, Nakazawa Y, et al. 22-Oxacalcitriol prevents progression of peritoneal fibrosis in a mouse model. Perit Dial Int. 2012;33:132–142.PubMedCrossRefGoogle Scholar
  29. 29.
    Benedetti A, DiSario A, Bendia E, Saccomanno, et al. H-Ras inhibition reduces rat liver fibrosis in vivo. Hepatology. 2000;32:302A.Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Rina Neeman
    • 1
  • Shirley Abramovitch
    • 2
    Email author
  • Efrat Sharvit
    • 1
  • Galit Elad-Sfadia
    • 3
  • Roni Haklai
    • 3
  • Yoel Kloog
    • 3
  • Shimon Reif
    • 2
    • 4
  1. 1.Sackler Faculty of MedicineTel Aviv UniversityTel-AvivIsrael
  2. 2.Department of PediatricsHadassah Ein-Kerem Medical CenterJerusalemIsrael
  3. 3.Department of Neurobiochemistry, The George S. Wise Faculty of Life SciencesTel-Aviv UniversityTel-AvivIsrael
  4. 4.Faculty of MedicineHebrew UniversityJerusalemIsrael

Personalised recommendations